Burkert Unveils New Manufacturing Facility in Pune to Bolster Indian Operations

This move is part of the company’s strategy to strengthen its local presence in India and meet rising demand for its regional products. 

Burkert Fluid Control Systems India, a global manufacturer specializing in liquid and gas control systems, has inaugurated its new manufacturing facility in Pune, Maharashtra. 

This move is part of the company’s strategy to strengthen its local presence in India and meet rising demand for its regional products. 

Located in Talegaon MIDC, the facility houses advanced machining centers, assembly lines, and testing units designed to optimize productivity and cater to India's industrial sector. 

The facility is set to produce over 30,000 valves and 500 systems annually, focusing on serving key clients such as Zydus, Alembic, Sun Pharma, Biocon, Bharat Biotech, and the Serum Institute of India.

Strategic Growth for Burkert in India

The Pune unit is initially set to employ 32 workers by the end of 2024, with plans to expand the workforce to 100 by next year. The plant’s production will focus on key products such as Mass Flow Controllers, Angle Seat Valves, Diaphragm Valves, and System Solutions. Future plans include phased expansions to diversify the product line.

“This facility brings us closer to our customers in India, allowing us to offer better service and faster delivery while also contributing to local employment,” said a Burkert spokesperson. 

The spokesperson also highlighted that technology transfer for unique systems, such as Zone 1 ATEX classification panels, has already been completed, ensuring that high-quality, localized production meets international standards.

Burkert has emphasized that the new facility is aligned with the company’s long-term goal of profitability in India. The Pune plant is expected to become profitable by 2028.

Boosting Indian Healthcare with Localised Production

By setting up production in India, Burkert aims to enhance its service to the healthcare sector, which relies on high-performance control systems for pharmaceutical manufacturing and other medical applications. Local production is expected to cut lead times for critical healthcare components significantly.

Burkert’s existing clients in India, such as Serum Institute and Bharat Biotech, are key players in vaccine manufacturing and biotechnology, which depend on precise flow control systems for operational efficiency. 

The Talegaon facility’s manufacturing output is expected to support these sectors, particularly in improving the availability and delivery of essential medical and pharmaceutical production components.

The new facility is also part of Burkert’s commitment to contributing to India’s ‘Make in India’ initiative by investing in local manufacturing and reducing dependence on imports.

Financial and R&D Commitment

Burkert’s global turnover is €710 million, and its workforce is over 3,700. The company invests 6.9% of its revenue in research and development, which is crucial to its competitive edge. 

Burkert India’s focus on R&D aims to tailor products to the specific needs of the Indian market, particularly in the healthcare, pharmaceutical, and biotechnology industries.

“We are committed to expanding our R&D efforts in India to serve the growing healthcare and industrial sectors better. This facility is a stepping stone toward that goal,” the company added in its statement.

The new facility is expected to support Burkert’s continued expansion in India, enabling the company to meet local demand more effectively while creating job opportunities. 

Stay tuned for more such updates on Digital Health News.